These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33129272)

  • 1. Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT.
    Patton H; Burchette R; Tovar S; Pio J; Shi J; Nyberg LM
    BMC Gastroenterol; 2020 Oct; 20(1):362. PubMed ID: 33129272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.
    Tapper EB; Challies T; Nasser I; Afdhal NH; Lai M
    Am J Gastroenterol; 2016 May; 111(5):677-84. PubMed ID: 26977758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
    Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
    PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
    Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
    Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial.
    Lim SL; Johal J; Ong KW; Han CY; Chan YH; Lee YM; Loo WM
    JMIR Mhealth Uhealth; 2020 Apr; 8(4):e14802. PubMed ID: 32281943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study.
    Commins I; Clayton-Chubb D; Melton S; Majeed A; Kemp W; Roberts SK
    Intern Med J; 2023 Nov; 53(11):2065-2072. PubMed ID: 36880362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
    Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
    Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.
    Armstrong MJ; Hazlehurst JM; Parker R; Koushiappi E; Mann J; Khan S; Philips A; Chandler L; Johnson J; Round M; Haydon G; Karamat MA; Newsome PN; Tomlinson JW
    QJM; 2014 Jan; 107(1):33-41. PubMed ID: 24131545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards collaborative management of non-alcoholic fatty liver disease: a 'real-world' pathway for fibrosis risk assessment in primary care.
    Hayward KL; McKillen BJ; Horsfall LU; McIvor C; Liew K; Sexton J; Johnson AL; Irvine KM; Valery PC; McPhail SM; Britton LJ; Rosenberg W; Weate I; Williams S; Powell EE
    Intern Med J; 2022 Oct; 52(10):1749-1758. PubMed ID: 34139066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
    Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
    World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and Referral Practices for Nonalcoholic Fatty Liver Disease by Race and Ethnicity in a Primary Care Clinic.
    Patil R; Nagaraj PK; Kuo HC; Noel G
    J Racial Ethn Health Disparities; 2023 Jun; 10(3):1392-1397. PubMed ID: 35556223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of a randomized mobile-technology lifestyle program in individuals with nonalcoholic fatty liver disease.
    Tincopa MA; Patel N; Shahab A; Asefa H; Lok AS
    Sci Rep; 2024 Mar; 14(1):7452. PubMed ID: 38548875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping.
    Hallsworth K; McPherson S; Anstee QM; Flynn D; Haigh L; Avery L
    J Med Internet Res; 2021 Jan; 23(1):e20491. PubMed ID: 33448929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.